OK
The Universal Selection Source:
Coatings Ingredients
Industry News

Affinergy Recruits Two Senior Executives to Lead Research & Development

Published on 2004-08-05. Author : SpecialChem

 

RESEARCH TRIANGLE PARK, N.C. -- Affinergy, Inc., a biomaterial coatings company with unique capabilities to regulate biological processes on the surface of synthetic materials, announced that it has hired Paul T. Hamilton, Ph.D. as Director of Research and Development and Wayne F. Beyer, Ph.D. as Director of Protein Chemistry.

"Paul and Wayne bring highly relevant scientific experience to Affinergy as well as proven management capabilities," said Peyton Anderson, CEO of Affinergy. "Great companies are built around great people and these key employees give us a strong foundation for growth. Paul and Wayne's expertise will help us fully leverage the commercial potential of Affinergy's technology and meet the needs of our business partners and shareholders."

"Affinergy's technology truly has the potential to transform the medical device industry," said Hamilton, who will manage all research operations for Affinergy. "After 20 years in science you learn to appreciate when something really special comes along - Affinergy is such a company. From my personal experience, I know the power and versatility of the underlying technology and am excited to drive its commercialization forward."

"Affinergy has a unique potential to immobilize proteins in ways that can dramatically improve existing devices as well as create new devices," said Beyer, who will manage the protein chemistry team at Affinergy. "We can unlock tremendous potential from the field of proteomics and get products to market in a short time frame. I look forward to working with our partners to functionalize their devices using Affinergy's technology and the tremendous potential of proteomics."

Paul Hamilton spent the last 7 years at Karo Bio USA (formerly Novalon Pharmaceuticals) where he served as Vice President of Research and Development. In this capacity, he managed 32 people and a $5 million operating budget for the U.S. operations. Hamilton was also responsible for the development of Karo Bio's phage display technology and peptide-based assay technology. Previously, he spent 11 years at Becton Dickinson in a variety of roles in cell biology and molecular biology. Hamilton earned his B.S. in microbiology from the University of Michigan and his M.S. and Ph.D. in microbiology at the Ohio State University.

Wayne Beyer previously served as Director of Proteomics Research and Rare Reagents R&D at Tripath Oncology where he managed a diverse team of 12 researchers discovering and developing biological markers for Oncology applications. These efforts lead to the release of three products in less than two years. He was responsible for his group's key business and development partnership with Becton Dickinson and Millenium Pharmaceuticals. Previously, he spent 8 years at Becton Dickinson in a variety of roles in medical devices, drug delivery, protein chemistry, and cell biology. Beyer was also a Research Associate Professor at Duke University Medical Center in the Department of Pathology, where he remains on the faculty as an Adjunct Assistant Professor of Pathology. He earned his BS in chemistry at University of West Florida and his Ph.D. in inorganic chemistry at NC State University.

About Affinergy

Affinergy's revolutionary "biological glue" is a platform technology designed to greatly improve the performance of medical devices by regulating the biology on their surfaces. Target opportunities include applications include to block biofilm formation, promote specific cell growth, and enable biomolecular immobilization. The coatings technology is highly modular, target-specific, and easy to apply in manufacturing. Affinergy can help medical device suppliers grow sales by differentiating existing devices as well as creating new products. By creating "tunable" bioactive surfaces on medical devices, Affinergy can contribute to the lowering of healthcare costs and improving of patient outcomes.

Source: Affinergy


FEICA 2018 European Adhesive and Sealant Conference and EXPO
Back to Top